APhA and Joint Statements

• Coalition Guiding Principles for Safe and Efficacious COVID-19 Vaccine Development, Distribution, Allocation, and Mass Immunization (October 22, 2020)
• APhA Hails HHS Announcement Authorizing Pharmacists to Administer COVID-19 Vaccines (September 9, 2020)
• APhA CEO Remarks on the NASEM Draft Framework for Equitable Allocation of a COVID-19 Vaccine (September 2, 2020)
• In Major Win, HHS Authorizes Pharmacists to Order and Administer Vaccines to Children Nationwide During the Public Health Emergency (August 19, 2020)
• APhA Statement Expresses Disappointment Over Absence of Temporary Provider Status Language in HEALS Act (July 28, 2020)
• Joint Statement of AMA, APhA, and ASHP on New FDA Action to Remove Emergency Use Authorization of Medications to Treat COVID-19: Physician and pharmacist groups seek to avert unintended barriers to evidence-based use of hydroxychloroquine and chloroquine (June 23, 2020)
• Updated: Joint Statement of AMA, APhA, and ASHP on Ensuring Access to Medicines (April 17, 2020)
• Updated: Pharmacy Organizations' Joint Policy Recommendations to Combat the COVID-19 Pandemic (April 3, 2020)
• APhA Guidance for Patients and Caregivers About Medication Supply During the Coronavirus Pandemic (March 19, 2020)
• APhA Issues Statement on Protections for Healthcare Providers During Coronavirus Pandemic (March 17, 2020)
• APhA Urges Insurers, PBMs to Immediately Remove Barriers on Prescription Drug Refills for Coronavirus Preparedness (March 13, 2020)

APhA and Joint Comment Letters

CMS

• APhA Comments: Fourth Interim Final Rule with Request for Comments (IFC) on Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency (January 4, 2021)
• Medicare and Medicaid Programs, Clinical Laboratory Improvement Amendments, and Patient Protection and Affordable Care Act: Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency (November 2, 2020)
• APhA Submits Comments Urging CMS to Maximize Use of Pharmacists for Nation’s Public Health Needs During COVID-19 (July 7, 2020) (Advocacy Summary)
• APhA Submits Comments Urging CMS to Remove Barriers on Pharmacist-Provided COVID-19 Testing and Telehealth Services (June 1, 2020)

DEA

• Letter to DEA on Signature Requirement for OTC Pseudoephedrine Products (April 17, 2020)

FDA

• APhA Statement for Virtual FDA Listening Session on Drug Compounding (June 22, 2020)
• Joint Letter to FDA to Exercise of Enforcement Discretion for Certain Dispenser Requirements Under the Drug Supply Chain Security Act (May 22, 2020)
• Letter to FDA Regarding Compounding Products in Shortage or Anticipated to be in Shortage During National Emergency (March 26, 2020) 
• Joint Pharmacy Comments on Policy for Temporary Compounding of Alcohol-Based Hand Sanitizer (March 20, 2020)

HHS

• Joint Letter Urges HHS to Allow Retired Pharmacists and Pharmacy Technicians to Serve as COVID-19 Vaccinators (February 2021)
• APhA Comments: Regulatory Relief to Support Economic Recovery; Request for Information (RFI) (December 28, 2020)
• APhA Comments: Request for Information (RFI) on Effective and Innovative Approaches/Best Practices in Health Care in Response to the COVID-19 Pandemic (December 24, 2020)
• APhA Comments: HHS Draft Vaccines National Strategic Plan 2021–2025 (December 3, 2020)
• National Pharmacy Associations Respond to Executive Order on Regulatory Relief to Support Economic Recovery (August 7, 2020) 
• Joint Pharmacy Request for Authorization for Licensed Pharmacists to Order and Administer COVID-19 Vaccines under the PREP Act (June 29, 2020) (Advocacy Summary)
• Joint Pharmacy Letter to Admiral Giroir (May 8, 2020) 
• APhA Recommendations to the President's Coronavirus Task Force (March 13, 2020)

Department of Labor

• Letter to OSHA Requesting Clarification of the Level of Protection for Pharmacists and Pharmacy Staff (April 1, 2020)

States

• APhA Urges the States to Include Community Pharmacists in Vaccine Distribution Plans (August 19, 2020) 
• Support Letter for Implementation of Ohio Provider Status Law (July 10, 2020) (Webpage)
• Joint Letter to Pennsylvania Request Laboratory Requirement Waiver: COVID-19 Testing by Pharmacists (May 27, 2020) 
• HHS Letter to States to Waive Restrictions on Scope of Practice During Coronavirus (March 24, 2020) 
• HHS Guidance to States to Waive Restrictions on Scope of Practice During Coronavirus (March 2020) 

Congress / Executive Office

• Joint Pharmacy Request to Appoint a Pharmacist to the COVID-19 Health Equity Task Force (February 12, 2021)
• Joint Letter to President Biden to Address Compounding Issues (January 19, 2021)
• Joint Letter to President Biden on Maintaining Vaccine and Supply Chain Resiliency (January 14, 2021)
• Joint PSPC Coalition Letter to Congressional Leaders (December 12, 2020)
• Joint Letter to Biden Transition Team with Public Health Recommendations and Meeting Request (December 2020)
• APhA Recommendations on Ways to Maximize the Use of Pharmacists to Prevent, Treat, Test and Respond to Coronavirus (July 24, 2020)
• APhA Comments on Senate HELP White Paper on Preparing for the Next Pandemic (June 26, 2020) (Advocacy Summary)
• Chart on Provisions Impacting Pharmacists in Senate-Passed Coronavirus Legislation (April 2020) 
• Joint Pharmacy Letter to Congress to Include DIR Fix in Coronavirus Legislation (March 20, 2020)
• Joint Pharmacy Letter to House to Include Provider Status in Coronavirus Legislation (March 20, 2020)
• Joint Pharmacy Letter to Senate to Include Provider Status in Coronavirus Legislation (March 20, 2020)
• APhA Letter to House and Senate Leadership on Coronavirus (March 18, 2020)

National Academies of Sciences, Engineering, and Medicine

• Joint Comments on the Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine (September 4, 2020)